Skip to main content
Equibles
ELAN logo

ELAN · Elanco Animal Health Inc · Documents

Track ELAN — free

Use ELAN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ELAN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$26.78 +0.28 (+1.06%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript
S&P 400 member Russell 1000 member Rebalance outlook locked
Market Cap
$13.39B
Shares
499.83M
Volume · Nov 13 5.38M Avg daily vol (3M) 5.33M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $4.72B up 6.2% 10-K filed Feb 24, 2026 Quarterly report FY2026 Q3 Revenue $1.27B up 11.3% 10-Q filed Nov 6, 2026 Latest results Elanco raises 2026 outlook after third-quarter growth 8-K filed Nov 6, 2026 Earnings call Q3 2026 earnings call Held Nov 6, 2026
2026
Nov 9
Investor event
9% growth drives leverage to 2.9 times

Elanco reported 9% organic growth and leverage of 2.9 times, while reaffirming 2027 targets of mid-single-digit revenue growth, high-single-digit EBITDA growth and low-double-digit earnings growth.

4 source passages
And it is my pleasure to introduce you to Bobby Modi, EVP of U.S. Pet Health, and Bob Van Hembergen, who is the chief financial officer of Elanco. Growth in the quarter was 9% organically, 11% reported, which included about a point of growth from AHV that we acquired here earlier this year. we were able to get leveraged at 2.9 times. That was a major milestone for the company. we have a tremendous amount of clarity around our 2027 business plan, and we'll be meeting with the board next week to present that. But just a high degree of confidence, what we did do is reiterate our algorithm that we shared at Investor Day in December last year, which we did say we expect to grow mid-single digits from 25 to 28. We expect EBITDA to grow at high single digits, and we expect earnings to grow at low double digits. Open the document at this passage
Nov 6
Earnings call
2026 outlook raised after third-quarter revenue grows 11%

Elanco Animal Health raised its 2026 organic constant-currency revenue growth outlook to approximately 8% from 6% to 7%, reported revenue guidance of $5.155 billion to $5.18 billion, and adjusted EPS guidance of $1.17 to $1.20.

Read from the first part of this long document
4 source passages
Good morning. Thank you for joining us for Elanco Animal Health's third quarter 2026 earnings call. Elanco delivered an outstanding third quarter, outperforming our commitments and growing revenue 11% on a reported basis or 9% in organic constant currency. We now expect organic constant currency revenue growth of approximately 8%, up from the previous range of 6% to 7%. This translates to reported revenue of $5.155 billion to $5.18 billion, with our assumption for foreign exchange tailwinds and AHV international contributions remaining unchanged. For adjusted EPS, we are raising our guidance by $0.06 at the midpoint, bringing the new range to $1.17 to $1.20. Open the document at this passage
Nov 6
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rises 11%, net income turns positive

Elanco reported revenue of $1,265 million, up 11%, and net income of $18 million versus a net loss of $34 million for the three months ended September 30, 2026.

Revenue $1.27B ▲ 11.3% Net income $18M Diluted EPS $0.04
Read from the MD&A section
6 source passages
Elanco is a global leader in animal health, dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets. Three Months Ended September 30, 2026 | 2025 | % Change (Dollars in millions) Revenue | 1,265 | 1,137 | 11% Net income (loss) | 18 | (34) | NM Open the document at this passage
Nov 6
Current report 8-K
Elanco raises 2026 outlook after third-quarter growth

Elanco Animal Health reported third-quarter 2026 revenue of $1.265 billion, up 11%, adjusted EPS of $0.27 and a 2.9x net leverage ratio. It raised 2026 revenue guidance to $5.155 billion to $5.18 billion.

Financial results
5 source passages
Revenue of $1.265 billion, an increase of 11% year-over-year; 9% organic constant currency growth Reported EPS of $0.04, Adjusted EPS of $0.27 Net leverage ratio of 2.9x Adjusted EBITDA Raising revenue guidance to $5.155 billion to $5.18 billion, or approximately 8% organic constant currency growth Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the third quarter of 2026, provided guidance for the fourth quarter of 2026, updated guidance for the full year 2026, and provided an early outlook for the full year 2027. Open the document at this passage
Sep 22
Investor event
BofA Securities Global Healthcare Conference 2026

Elanco targets mid-single-digit revenue growth, high-single-digit EBITDA growth and low-double-digit EPS growth through 2028, while advancing 15 clinical projects toward five to six pipeline additions by 2031.

Aug 5
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $1.37B ▲ 10.2% Net income $54M ▲ 390.9% Diluted EPS $0.11 ▲ 450.0%
May 6
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $1.37B ▲ 14.9% Net income $57M ▼ 14.9% Diluted EPS $0.11 ▼ 15.4%
Feb 24
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $4.72B ▲ 6.2% Net loss $232M Diluted EPS -$0.47
2025
May 7
Quarterly report 10-Q FY2025 Q1, ended Mar 31
Quarterly report for FY2025 Q1
Revenue $1.19B ▼ 1.0% Net income $67M ▲ 109.4% Diluted EPS $0.13 ▲ 116.7%
Feb 25
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $4.44B ▲ 0.5% Net income $338M Diluted EPS $0.68
2024
Showing 1–50 of 179 documents
Key facts CIK 1739104 CUSIP 28414H103 13F (30d) 427 filings 388 filers Visit website Investor relations